Baseline sUA measurement was 6.90 ± 1.19 mg/dL, with 23.6% having tophi. Both lesinurad-treated groups had significantly increased proportions of patients achieving sUA targets compared with placebo plus allopurinol-treated patients. Approximately twice as many patients achieved these targets at Month 6. At Month 6, sUA < 6 mg/dL, lesinurad 200 mg results were 54%, lesinurad 400 mg results were 59% and placebo results were 23%. There were no significant differences observed between groups in mean rate of GFRT or with complete target tophus resolution. Safety was similar to CLEAR 1. Lesinurad combined with allopurinol was well tolerated and met study endpoints without severe toxicity.
Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
References
- Saag K, Fitz-Patrick D, Kopicko J, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: Results from a phase 3 study in gout patients having an inadequate response to standard of care (CLEAR 1). Ann Rheum Dis. 2015 June; 74(Suppl2):540. Abstract FRI0320. doi: 10.1136/annrheumdis-2015-EULAR.3273
- Bardin T, Keenan R, Khanna P, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: Results from a phase 3 study in gout patients having an inadequate response to standard of care (CLEAR 2). Ann Rheum Dis. 2015 June; 74(Suppl2):545. Abstract FRI0333. doi: 10.1136/annrheumdis-2015-EULAR.1238
